New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage ...

A meta-analysis of recent clinical trials evaluating β-blockers as treatment for patients with acute myocardial infarction ...

Delcath Systems announced that subgroup analyses from its phase 3 FOCUS study of the FDA-approved HEPZATO KIT for unresectable metastatic uveal melanoma were published in the Journal of Cancer ...

The phase 3 IMforte trial(NCT05091567) demonstrated benefit for expanding on maintenance immunotherapy in extensive-stage ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...

Delcath Systems (DCTH) announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication was published in the Journal of Cancer Research and Clinical Oncology.

Efforts to improve reporting clinical trial results have led to the development of guidelines such as those recommended by the CONSORT group. 3,4 Transparent and comprehensive reporting of subgroup ...

Introduction Many neonatal deaths are avoidable using existing low-cost evidence-based interventions. This study evaluated ...

Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...